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REVIEW

Evolving Role for Pharmacotherapy in NAFLD/NASH
Suzanna L. Attia1, Samir Softic1,2,3 and Marialena Mouzaki4,*

Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent, dynamic disease that occurs across the age spectrum and
can lead to cirrhosis and hepatocellular carcinoma. There are currently no US Food and Drug Administration (FDA) approved
treatments for NAFLD; however, this is a field of active research. This review summarizes emerging pharmacotherapies for
the treatment of adult and pediatric NAFLD. Investigated pharmacotherapies predominantly target bile acid signaling, insulin
resistance, and lipid handling within the liver. Three drugs have gone on to phase III trials for which results are available. Of
those, obeticholic acid is the single agent that demonstrates promise according to the interim analyses of the REGENERATE
trial. Obeticholic acid showed reduction of fibrosis in adults with nonalcoholic steatohepatitis (NASH) taking 25 mg daily for
18 months (n = 931, reduction in fibrosis in 25% vs. 12% placebo, P < 0.01). Ongoing phase III trials include REGENERATE and
MAESTRO-NASH, which investigates thyroid hormone receptor-β agonist MGL-3196. Outcomes of promising phase II trials
in adults with NASH are also available and those have investigated agents, including the fibroblast growth factor (FGF)19
analogue NGM282, the GLP1 agonist liraglutide, the FGF21 analogue Pegbelfermin, the sodium glucose co-transporter 2
inhibitor Empagliflozin, the ketohexokinase inhibitor PF-06835919, the acetyl-coenzyme A carboxylase inhibitor GS-0976,
and the chemokine receptor antagonist Cenicriviroc. Completed and ongoing clinical trials emphasize the need for a more
nuanced understanding of the phenotypes of subgroups within NAFLD that may respond to an individualized approach to
pharmacotherapy.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THIS
TOPIC?
✔ NAFLD affects up to one billion individuals globally
and is the most common cause of elevated liver enzymes in children. Mechanisms contributing to hepatic
steatosis and fibrosis include increased dietary fat intake, alterations in lipid generation and transport, and
the influences of insulin resistance, inflammation, and
oxidative stress. Despite prior clinical trials targeting
these mechanisms, consistently effective pharmacotherapy remains lacking.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ This study addresses the question of what novel pharmacotherapies for NAFLD in stage 2 or 3 clinical trials
exist and investigates their strengths and limitations.

Nonalcoholic fatty liver disease (NAFLD) affects up to 1 billion individuals worldwide1 and is the most common cause
of elevated liver enzymes in children. End-stage liver disease and/or hepatocellular carcinoma secondary to NAFLD
are among the leading causes of liver failure in adults in the
United States. Effective and affordable treatments to reduce
1

WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔ This study shows that novel pharmacotherapies for
NAFLD are limited and not yet ready for clinical use.
The only phase 3 trial to date with encouraging results
is REGENERATE; this study shows the potential for obeticholic acid over placebo to improve hepatic fibrosis but is
limited by its small effect in only one quarter of subjects.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
✔ This study shows that novel pharmacotherapy for
NAFLD is still an active and highly-needed area of ongoing
investigation. This study suggests that in the future, patients with NAFLD will likely require combination therapy
in order to address the multiple and potentially individualized mechanisms of their hepatic steatosis and fibrosis.

the medical and societal burden of this increasingly prevalent condition are urgently needed.2,3 NAFLD represents a
spectrum of diseases ranging from hepatocellular fat deposition (nonalcoholic fatty liver) to steatohepatitis (nonalcoholic
steatohepatitis (NASH) with or without fibrosis) to cirrhosis.
NAFLD is a dynamic disease that can progress to cirrhosis,
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but in a small percent of patients it may also spontaneously
regress.4 With the exception of cirrhosis, the histologic findings associated with NAFLD/NASH are generally reversible
with treatment. The most important treatment is lifestyle
modification leading to weight loss and enhanced physical
activity.5 Lifestyle interventions, however, have proven challenging both to implement and to sustain over time; this
underscores the need for effective pharmacotherapy.6 The
objective of this review is to summarize the current medical
literature on emerging pharmacotherapy for the treatment of
both adult and pediatric patients with NAFLD.
PATHOPHYSIOLOGY
NAFLD is the result of multiple, often concurrent, hits to
the liver that originate from dietary overnutrition, impaired
hormonal signaling (particularly insulin), defects in cellular metabolism that regulate hepatocellular lipid handling, changes
in the intestinal microbiome in the context of a compromised
intestinal barrier, and augmented proinflammatory/profibrotic
processes. The pathogenesis of NAFLD has been extensively
reviewed elsewhere.7 Briefly, steatosis occurs when there is
an imbalance between the mechanisms that regulate lipid
handling within the liver. Sources of hepatic fat include dietary
intake, fatty acid flux to the liver from adipose tissue, as well
as hepatic de novo lipogenesis (e.g., conversion of carbohydrates into fatty acids by the hepatocyte).8 Insulin resistance
is an important driver of lipogenesis in the context of NAFLD.9
Mechanisms to attenuate hepatic steatosis include increased
mitochondrial fatty acid oxidation, decreased hepatic lipogenesis, and enhanced lipid export from the hepatocytes in
the form of very low-density lipoproteins. When there is an
imbalance between input/synthesis vs. export/oxidation of
hepatocellular fat, hepatic steatosis develops. Furthermore,
the accumulation of toxic lipid species can trigger the development of lipotoxicity, oxidative stress, as well as immune cell
and stellate cell activation, ultimately leading to the development of hepatic inflammation and fibrosis.10 Gene expression
regulated by PNPLA3, and TM6SF2, bile acid signaling,
AMPK signaling, insulin, and adipokine signaling modulates
hepatocellular lipid handling.11,12 Recent data suggest that intestinal health and particular gut barrier integrity is crucial to
prevent microbial signals (e.g., endotoxemia and/or bacterially derived ethanol) from contributing to the pathogenesis of
NAFLD.13,14 Treatment approaches investigated to date have
targeted many of these mechanisms (Figure 1).
SUMMARY OF PRIOR TRIALS INVESTIGATING
MEDICAL OPTIONS FOR THE TREATMENT OF NAFLD
Various treatments have been investigated for the management of both adult and pediatric NAFLD.
• Metformin: Metformin has been studied in both adults
and children with NAFLD. In adults, a wealth of
data have shown that metformin can improve serum
aminotransferase elevations and ameliorate insulin
resistance; however, it does not have a meaningful
impact on liver histology.15,16 Similarly, in children,
metformin does not alter histological outcomes.17
Clinical and Translational Science

• Thiazolidinediones (TZD): Pioglitazone has been studied in adults with NASH (with and without type 2 diabetes mellitus (T2DM)) and is superior to placebo in
resolving NASH, reducing (necro)inflammation, and
fibrosis.18 Its use is associated with weight gain, however, a significant concern for patients with NAFLD, as
well as osteopenia and increased risk of fractures in
older adults.
• Vitamin E: The antioxidant vitamin E has been studied
in both nondiabetic adults and children with NAFLD.
In adults, vitamin E is superior to placebo in improving
histologic components of NASH. However, due to the
lack of data from patients with diabetes, its use is not
recommended in diabetics with NASH.18 In children,
vitamin E is also successful at improving histology
(e.g., NASH resolution) in a proportion of patients.17
• Other treatments: Various other treatments have been
studied for the treatment of NAFLD/NASH. These include probiotics/prebiotics/synbiotics and omega-3
polyunsaturated fatty acids, among others. Probiotics
and prebiotics have a beneficial impact on serum aminotransferase levels and other markers of metabolic
dysregulation but have not been studied adequately
in well-designed trials with histologic end points.19
Omega-3 fatty acids have been extensively studied,
predominantly in adults, and although they are beneficial from a steatosis reduction stand point, they do not
impact key histological outcomes such as inflammation and fibrosis.20
NOVEL THERAPIES
There are multiple novel pharmacotherapies in various
phases of investigation (Figure 2). The drugs that have
gone through phase III investigations are summarized in
Table 1. Herein, we discuss the most notable medications
studied grouped by mechanism of action.
Bile acid signaling
Obeticholic acid. Obeticholic acid (OCA) is an farnesoid X
receptor (FXR) agonist that has been extensively investigated
for the treatment of NAFLD. FXR agonism has been studied
because FXR is a bile acid receptor that exerts multiple
beneficial metabolic effects. FXR contributes to glucose
regulation at both the hepatic (regulating glycogenolysis
and gluconeogenesis) and the peripheral level (modulating
insulin sensitivity in the muscle and the adipose tissue). It
facilitates intrahepatic lipid handling (balancing de novo
lipogenesis and fatty acid oxidation) and also exerts antiinflammatory effects.12 Following the encouraging results
of the “FLINT” trial, a phase IIb randomized controlled
trial (RCT), which showed superiority of 25 mg of OCA
vs. placebo at reducing NAFLD activity score (NAS) by 2
points without fibrosis worsening at 72 weeks of treatment
in adults with NASH,21 a phase III trial followed. The latter,
called “REGENERATE,” is currently underway; the results
of its interim analysis recently became available.22 In
REGENERATE, 10 mg of OCA daily were compared against
25 mg of OCA daily vs. placebo. Of the 1,968 patients
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Figure 1 Tissue specific pathways targeted by the novel pharmacotherapies. Novel therapeutics under investigation for treatment
of nonalcoholic fatty liver disease target metabolic pathways in the liver and other tissue. Fructose metabolized in the liver supports
de novo lipogenesis. PF-06835919 targets ketohexokinase (KHK), the rate-limiting enzyme of fructose metabolism. Conversion of
acetyl-CoA to malonly-CoA by acetyl-CoA carboxylase (ACC) is the first committed step in lipogenesis. Malonyl-CoA is an inhibitor of
carnitine palmitoyltransferase 1 alpha, the rate-limiting enzyme of fatty acid metabolism. GS-0976 is an inhibitor of ACC, thus it prevents
lipogenesis and increases fatty acid oxidation. However, increased acetyl-CoA pool can serve as a substrate for cholesterol synthesis.
Once fat is made in the liver, it can be oxidized in the mitochondria to generate energy. Elafibranor is a peroxisome proliferator-activated
receptors alpha/delta (PPARα/δ) agonist that increases fatty acid oxidation. MGL-3196 and VK2809 are thyroid hormone receptor beta
(THR-β) agonists that increase the transcription of genes to upregulate mitochondrial fatty acid oxidation. Fibroblast growth factor 19
(FGF19) analogue NGM282 and Pegbelfermin, as well as PEGylated human FGF21, work in the liver and other tissues via fibroblast
growth factor receptor 4 (FGFR4) to increase glucose utilization and fatty acid oxidation. Whereas FGF21 is made in the liver, FGF19 is
made in the intestine through FXR activation. Obeticholic acid (OCA) is a semisynthetic bile acid that is a highly potent FXR agonist in
the liver and the intestine. Activation of FXR in the liver can decrease conversion of cholesterol to bile acids, so a common side effect
of OCA is increased serum cholesterol. Lipids made in the liver, but not oxidized, can be excreted from the liver to be utilized or stored
in other organs, such as adipose tissue. Thiazolidinediones (TZDs) are PPAR gamma (PPARγ) agonists that increase the storage of
fatty acids in adipocytes. As such, they create a sink for excess fat from the liver to be deposited in the adipose tissue; thus, they
can also cause weight gain. MSDC-0602K is a second generation PPARγ agonist that has fewer systemic side effects. Liraglutide is
an analogue of the gut-secreted hormone glucagon-like peptide 1 (GLP-1), which increases glucose-stimulated insulin secretion. It
also decreases gastric emptying leading to decreased appetite and weight loss. Empagliflozin is a sodium-glucose transport protein
2 (SGLT-2) inhibitor that works on the kidney to prevent glucose reabsorption, leading to calorie loss via glucosuria. Agonists are in
GREEN color whereas antagonists are in RED.

www.cts-journal.com
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Phase 2a

Phase 2b

•PPAR agonists: La branor, Saroglitazar
•GLP1 agonists: Cotadutide
•FGF21 agonists: Pegbelfermin
•SGLT2 inhibitors: Empagl lozin
•Ketohexokinase inhibitors: PF-06835919
•Thyroid hormone receptor beta (THR-β) agonists: MGL-3196 and VK2809
•Acetyl-coenzyme A carboxylase (ACC) inhibitors: GS-0976
•Caspase inhibitors: Emricasan
•Other: IMM-124E (colostrum product), Silymarin (milk thistle extract), combinations:
NCT03987074 (semaglutide, rsocostat, cilofexor)

•FGF19 analogues: NGM282
•PPAR agonists: Ela branor, MSDC-0602K
•GLP1 agonists: Liraglutide
•Combination therapies: NS-0200 (leucine-metformin-sildena l)
•CC Chemokine receptors 2/5 antagonists: Cenicriviroc
•Galectin inhibitors: Balapectin

•FXR agonists: Obeticholic acid
•Caspase inhibitors: Emricasan
•ASK1 inhibitors: Selonsertib

Phase 3

Figure 2 Summary of novel medications at the various stages of investigation (active or completed).

enrolled, 931 with stages 2 and 3 fibrosis were included
in the interim analysis, which was performed at 18 months
of treatment. The primary outcomes were either fibrosis
improvement (≥ 1 stage) without NASH worsening or NASH
resolution without fibrosis worsening. OCA at 25 mg daily
was superior to placebo at improving fibrosis (outcome
met in 25% of patients vs. 12% on placebo, P < 0.01);
however, OCA did not meet the other primary outcome of
NASH resolution. The most common side effect was mild
to moderate pruritus, which affected 51% of those treated
with 25 mg OCA vs. 19% of those receiving placebo.
In post hoc analyses of the phase IIb FLINT trial, of the
200 patients with paired biopsies in the beginning and at the
end of the 72 week intervention, there was a trend toward increased likelihood of weight loss with the use of OCA (44%
of OCA vs. 32% of placebo-treated patients lost at least 2%
of their baseline weight, P = 0.08). This was an added benefit
to OCA’s therapeutic impact, in addition to reduced serum
aminotransferases and improved liver histology (reduction
in NAS).23 However, OCA was associated with an increase
in serum alkaline phosphatase, low-density lipoprotein-C
(LDL-C), and hemoglobin A1c levels. Combination treatment
of OCA with a statin (e.g., 25 mg OCA + 10 mg atorvastatin) has subsequently proven efficacious in preventing the
LDL-C increase seen with OCA monotherapy.24
Clinical and Translational Science

NGM282. NGM282 is a humanized fibroblast growth
factor (FGF)19 analogue, which acts on the same
pathway as intestinal FXR agonists. Specifically, FGF19
is released following the activation of intestinal FXR, with
similar downstream effects as those noted following FXR
activation.12 Following beneficial effects of treatment with
FGF19 noted using magnetic resonance imaging-proton
density fat fraction (MRI-PDFF),25 Harrison et al. reported
the results of a 12-week open label multicenter trial of
NGM282 for the treatment of NASH.26 Patients receiving
subcutaneous NGM282 at either 1 or 3 mg with paired
biopsies 12 weeks apart were included in the analyses
(n = 43). NGM282 at 3 mg decreased fibrosis by ≥ 1 stage
without NASH worsening in 42% of patients and improved
NAS by ≥ 2 points without fibrosis worsening in 63% of
subjects. A 24-week phase IIb trial of NGM282 for the
treatment of NASH is currently under way (NCT03912532).
Treatments that improve insulin resistance/metabolic
dysregulation
Peroxisome proliferator-activated receptor agonists.
Peroxisome proliferator-activated receptor (PPAR) isoforms
alpha, delta, and gamma are nuclear hormone receptors
with the potential to ameliorate NAFLD owing to their effects
on lipid metabolism (e.g., increased mitochondrial fatty
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Emricasan not superior to placebo
• Change in hepatic venous
pressure gradient

NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.

Emricasan:
• 5mg twice daily
• 25mg twice daily
• 50mg twice daily
× 24 weeks
NASH-related cirrhosis with
severe portal hypertension
(n = 263)
ENCORE-PH
Garcia-Tsao et al. J Hepatol
2019
Conatus Pharmaceuticals

Placebo

Selonsertib not superior to placebo
• NASH resolution
• Progression to cirrhosis
Selonsertib:
• 6 mg daily
• 18 mg daily
×48 weeks
NASH and bridging fibrosis (3)
(n = 802)
NASH and compensated
cirrhosis (4) (n = 877)
Stellar-3 and 4
Harrison et al. J Hepatol 2020
Gilead

Placebo

25 mg obeticholic acid superior
to placebo at improving fibrosis
(seen in 25% vs. 12% on
placebo, P < 0.01)
• Fibrosis improvement (≥ 1 stage)
without NASH worsening
• NASH resolution without fibrosis
worsening
Obeticholic acid:
• 10 mg daily
• 25 mg daily×
18 months
NASH with stages 1–3 fibrosis
(n = 931, results of interim
analysis)
Regenerate
Younossi et al. Lancet 2019
Intercept Pharmaceuticals

Placebo

Intervention/duration
Population
Study/funding

Table 1 Phase III trials for the treatment of NAFLD/NASH

Comparison

Primary outcome

Results

15

acid oxidation), insulin sensitivity, and inflammation.27 Both
PPAR alpha and delta receptors facilitate fat metabolism
(e.g., fatty acid oxidation), whereas PPAR delta also has
anti-inflammatory effects.27 PPAR gamma helps regulate
glucose metabolism as well as fat cell differentiation and
fatty acid storage.27 Ratziu et al. evaluated the combined
PPAR α/δ agonist elafibranor in a 52 week phase II
RCT that compared 120 mg vs. 80 mg of elafibranor vs.
placebo in adults with NASH (n = 91–93 per arm).28 The
primary outcome was reversal of NASH (score 0 in at least
1 of the components of NAS, namely steatosis, lobular
inflammation, ballooning) without fibrosis worsening. Per
original protocol definition, there was no difference for any
dose of elafibranor on primary outcome. However, in a post
hoc analysis, a modified definition of the primary outcome
was introduced showing that reversal of NASH occurred
when ballooning resolved in the context of no or minimal
lobular inflammation. Per this analysis, the 120 mg dose led
to improvement in 19% vs. 12% in those receiving placebo
(P = 0.045). There was no difference in patients receiving
the 80 mg dose. Adverse outcomes were similar among
intervention and control arms. Secondary effects included
lower LDL-C and triglycerides with higher high-density
lipoprotein in the intervention groups vs. control. Ongoing
clinical trials include NCT03008070 assessing efficacy and
safety of pan-PPAR agonist IVA337/lanifibranor at 800 mg
and 1,200 mg daily vs. placebo for 24 weeks in adult
patients with moderate to severe NASH without cirrhosis.
Another ongoing trial is NCT03639623, a phase IIA, single
center, open-label, single-arm, 24-week study to evaluate
the safety, tolerability, and efficacy of PPAR alpha/gamma
agonist Saroglitazar magnesium 4 mg in liver transplant
recipients with NAFLD (EVIDENCES VIII).
MSDC-0602K is a second-generation TZD, a PPAR
gamma agonist. Second generation TZDs, like MSDC0602K, do not have the typical TZD side effects of edema,
fractures, and hypoglycemia due to their mode of action. In
the EMMINENCE study, Harrison et al. investigated MSDC0602K in a phase IIb trial in adults with NASH (defined as
NAS ≥ 4; with a score ≥ 1 in each NAS component) and
fibrosis stages 1–3.29 After 52 weeks of daily oral MSDC0620K at 62.5 mg vs. 125 mg vs. 250 mg vs. placebo given
to n = 99 to 101 participants per arm, they found no difference in their primary outcome of improved NAS.
Glucagon-like peptide-1 agonists. Glucagon-like
peptide-1 (GLP1) agonists improve glucose homeostasis
by enhancing glucose-dependent insulin secretion and
inhibiting the release of glucagon from the pancreas. They
also delay gastric emptying and, when used to treat T2DM,
contribute to weight loss. These effects are ideal for patients
with NAFLD, as they are typically overweight or obese and
have insulin resistance and/or diabetes. The GLP1 agonist
liraglutide was investigated in a 42-week phase II RCT
(1.8 mg subcutaneous liraglutide daily vs. placebo) for the
treatment of NASH.30 The primary outcome was definite
NASH resolution without worsening of fibrosis. The relative
risk of NASH resolution was 4.3 (P = 0.019) with the use of
liraglutide, which also led to weight loss and was overall
well-tolerated. Cotadutide, a dual receptor agonist for
www.cts-journal.com
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GLP1 and glucagon, was recently shown to be superior to
liraglutide in reducing weight and serum aminotransferases
in an adult cohort of patients with diabetes.31 These
encouraging results are now being investigated further in a
phase II trial specific to patients with NASH (NCT04019561).
Fibroblast growth factor 21 agonists. FGFs are
hormones key to cell growth and differentiation.32 FGF21
is transcriptionally regulated, in part, by PPAR alpha and
upregulates fatty acid oxidation. FGF21 can also attenuate
proinflammatory signals. Sanyal et al. investigated the
FGF21 analogue pegbelfermin (BMS-986036) given via
subcutaneous injection in a 16-week phase IIa trial.33 The
trial recruited patients with NASH, stages 1–3 fibrosis, and
≥ 10% hepatic fat fraction by MRI-PDFF and compared
10 mg daily, vs. 20 mg weekly pegbelfermin vs. placebo
(24–26 adults in each group).33 Both daily and weekly
treatments were superior to placebo in achieving the
primary outcome of PDFF reduction (10 mg daily: −6.8%,
P = 0.0004 vs. 20 mg weekly: −5.2, P = 0.008 vs. placebo
−1.30%) with no difference for those with or without
T2DM. Anti-pegbelfermin and anti-FGF21 antibodies were
detected in the majority of patients, decreased in most by
the end of treatment, and did not affect outcome. Notable
adverse outcomes were diarrhea and nausea.
Sodium glucose co-transporter 2 inhibitors. Sodium
glucose co-transporter 2 (SGLT2) inhibitors act by inhibiting
reabsorption of glucose in the kidney and can also inhibit
de novo lipogenesis in the liver.34 Due to their action, they
contribute to weight loss and improvements in systolic
blood pressure.35 SGTL2 inhibitors have been used for
the treatment of T2DM and more recently have been
investigated for the treatment of NAFLD, particularly in
patients with diabetes, in small studies. Empagliflozin (10 mg
daily ×20 weeks) was compared against standard treatment
for diabetes in a cohort of adults with diabetes with NAFLD
with a primary outcome of change in MRI-PDFF.36 Although
empagliflozin was superior to the standard of care at
reducing the fat fraction, the reduction was modest (only 5%
from baseline), and the difference from the control group at
20 weeks was only 4%. No significant adverse events were
noted in this study. The effect of SGLT2 inhibitors on liver
histology remains to be investigated.
Fructose metabolism. Dietary fructose strongly increases
hepatic de novo lipogenesis37,38 and decreases hepatic
fatty acid oxidation,39 thus predisposing to development of
NAFLD. The rate-limiting enzyme of fructose metabolism
is ketohexokinase (KHK), which is increased in adult
subjects with biopsy-proven NAFLD40 and in obese
adolescents with more severe forms of NAFLD.38 In animal
studies, knockdown of KHK improves NAFLD and insulin
resistance.38,41 Small molecule inhibitors of KHK have been
of interest to pharmaceutical industry for a long time, but
initial KHK inhibitors lacked specificity.42,43 More recently,
Pfizer developed a potent reversible inhibitor of human
KHK.44 In a phase II study of 53 subjects with NAFLD
(> 6% liver fat assessed by MRI-PDFF), subjects received
either placebo or the KHK inhibitor PF-06835919 at 75 or
Clinical and Translational Science

300 mg of once daily dosing for 6 weeks (NCT03256526).
Participants treated with 300 mg of KHK inhibitor showed
a 26.5% reduction in PDFF (P = 0.039) from baseline as
compared with the placebo group. A dose-dependent
trend in decrease from baseline was also observed for
liver enzymes (alanine aminotransferase (ALT), aspartate
aminotransferase, and gamma glutamyltransferase), in a
homeostasis model of assessment of insulin resistance,
and in markers of systemic inflammation (hs-CRP, IL-6,
and increased adiponectin) in the 300 mg group relative to
placebo.45 Fructose may also directly and indirectly induce
hepatic insulin resistance46 leading to hyperinsulinemia; this
further stimulates hepatic lipogenesis.47 Due to the effect of
fructose on hyperinsulinemia, the encouraging initial results
of PF-06835919 are being further investigated in a phase II
study of 150 participants with MRI-PDFF liver fat of > 8%
and T2DM treated with placebo or PF-06835919 at 150 mg
or 300 mg once daily for 16 weeks (NCT03969719).
Thyroid hormone receptor. Thyroid hormone regulates
glucose and lipid metabolism, food intake, and the oxidation
of fatty acids.48 Systemic thyroid hormone replacement
therapy, however, is not indicated for the treatment of
obesity and NAFLD due to adverse cardiac and bone effects.
Recently, a more selective thyroid hormone receptor beta
(THR-β) agonist has been developed to optimize beneficial
effects on the liver while minimizing the actions on heart
and bone that are mainly mediated by THR alpha (THR-α).
Two THR-β agonists, MGL-3196 and VK2809, are currently
in clinical development.
In a phase II study of 125 adults with biopsy-confirmed
NASH, MGL-3196 at 80 mg daily dose with ± 20 mg dose
adjustment resulted in 32.9% relative reduction of hepatic
fat as assessed by change in MRI-PDFF compared with
10.4% reduction in placebo-treated patients after 12 weeks
(NCT02912260). After 36 weeks of treatment, MGL-3196
resulted in a sustained 37.3% reduction in liver fat compared with 8.5% reduction in the placebo treated group. In
spite of reduced liver fat at 12 weeks, there was no difference in serum ALT; but with longer exposure at 36 weeks,
a significant reduction in ALT was observed. NASH resolution, defined as ballooning score of 0, inflammation score
of 0 or 1, with ≥ 2-point reduction in NAS on liver biopsy,
was a secondary end point in the study. NASH resolution
was observed in 27% of patients treated with MGL-3196
compared with 6% in those receiving placebo (P = 0.018)
at 36 weeks. Similarly, NASH resolution was significantly
greater (P = 0.017) in the MGL-3196 group (46%) compared with placebo (19%) in patients who lost < 5% of
body weight. Interestingly, overall improved outcomes in
subjects treated with MGL-3196 occurred with no change
in total body weight, indicating that improved liver metabolism is sufficient to induce NASH resolution. Whereas
several other classes of medication under development for
the treatment of NASH result in dyslipidemia, treatment with
MGL-3196 resulted in reductions in multiple atherogenic
lipids including LDL-C, triglycerides, apolipoprotein B, and
CIII. Side effects of MGL-3196 therapy were minimal and
mainly included transient diarrhea. These promising findings
are being further explored in MAESTRO-NASH, a phase III
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clinical trial in patients with NASH and stage F2–F3 fibrosis
(NCT03900429).
A second THR-β selective agonist VK2809 is being evaluated for treatment of NASH in a phase IIa clinical study
(NCT02927184). In this study, 45 patients with liver fat content ≥ 8% as assessed by MRI-PDFF, LDL-C ≥ 110 mg/dL,
and triglycerides ≥ 120 mg/dL were randomized to receive
either oral VK2809 doses of 5 mg daily, 10 mg every other
day, 10 mg daily, or placebo for 12 weeks. At the end of
the study, median relative change from baseline in liver fat
content was 53.8% for 5 mg daily (P = 0.0001), 56.5% for
10 mg every other day (P = 0.0018), and 59.7% for 10 mg
daily (P = 0.0004), vs. 9.4% for placebo.49 Surprisingly, ALT
levels increased transiently at the onset of treatment, but
after 12 weeks of administration, they were not different in
subjects that received VK2809 or placebo.50 This study is
being followed up by VOYAGE, a phase IIb study of 337 subjects with biopsy proven NASH (NAS ≥ 4) and MRI-PDFF
liver fat fraction ≥ 8% (NCT04173065). This is a 5-treatment
arm study of placebo and VK2809 at 1.0, 2.5, 5.0, or 10 mg
daily administered for 52 weeks.
Other
Acetyl-coenzyme A carboxylase inhibitors. Acetylcoenzyme A carboxylase (ACC) inhibitors impede de novo
lipogenesis. GS-0976 is an ACC1 and ACC2 inhibitor
investigated by Loomba et al. in a phase II clinical trial.51
Patients with NASH and stages 1–3 fibrosis or MRI-PDFF
≥ 8% and liver stiffness ≥ 2.5 kPa were randomized to
receive 20 mg GS-0976 (n = 49), 5 mg GS-0976 (n = 51),
or placebo (n = 26) orally once daily for 12 weeks. The
primary end point of this trial was safety. The 20 mg
dose was superior to placebo at reducing the MRI-PDFF
(median change in hepatic fat fraction with 20 mg: −29%,
P = 0.0002; vs. 5 mg: −13%, P = 0.43; vs. placebo: −8%).
Adverse outcomes were nausea, abdominal pain, diarrhea,
and headache. Hypertriglyceridemia was seen in both
intervention groups and was concentrated especially in
participants with TG ≥ 250 mg/dL at baseline. This resolved
spontaneously or with treatment by week 12.
Combination therapies. L-leucine alters lipid and energy
metabolism and insulin sensitivity through activation of
the AmPK/Srtiun 1 pathway. L-leucine in combination with
metformin and sildenafil has an additive impact on the
Srtiun 1pathway through endothelial nitric oxide synthase
activation. NS-0200 is a combination of leucine-metforminsildenafil recently investigated by Chalasani et al. in a small
phase IIb clinical trial.52 They randomized adults (n = 24–32
per arm) with NAFLD and MRI-PFF ≥ 15% to a 16 week
course of twice daily placebo, low-dose (1.1 g leucine/0.5 g
metformin/0.5 mg sildenafil), or high-dose NS-0200 (1.1 g
leucine/0.5 g metformin/1.0 mg sildenafil). The primary
outcome of change in PDFF did not differ between
treatment groups and placebo; however, dose-dependent
decreases in HgbA1c were noted in the NS-0200 arms
compared with placebo (placebo adjusted decreases of
0.21%, P = 0.002, and 0.17%, P = 0.016) for low-dose and
high-dose, respectively). Adverse effects included blurry
vision, diarrhea, nausea, and erosive gastritis.

Other ongoing clinical trials of combination therapies include phase II investigation of semaglutide, firsocostat, and
cilofexor combination therapy (NCT03987074). Semaglutide
is a GLP1 agonist, firsocostat is an acetyl-CoA carboxylase
inhibitor, and cilofexor is a bile acid FXR agonist.
Anti-apoptosis/anti-inflammatory agents
Emricasan. Emricasan is a pan-caspase inhibitor and
given the involvement of caspases in inflammation,
apoptosis, and necrosis, emricasan has the potential to
reduce portal pressure and fibrosis. Garcia-Tsao et al.
investigated emricasan in a phase III clinical trial of NASHrelated cirrhosis with severe portal hypertension.53 Adults
with NASH-related compensated and decompensated
(25% of participants) cirrhosis were randomized to 5, 25, or
50 mg vs. placebo orally twice daily for 24 weeks (n = 65–67
per arm). Emricasan failed to achieve the primary outcome
of change in hepatic venous pressure gradient (HVPG);
however, there was a modest trend toward improved HVPG
in the compensated patients with higher baseline HVPG
receiving any dose of Emricasan. There were no notable
adverse events.
A more recent phase II clinical trial of emricasan assessed
the effect of 5 mg or 50 mg twice daily vs. placebo for
72 weeks in adults (n = 105–107 per arm) with histologically-confirmed NASH and stage F1–F3 fibrosis.54 There was
no difference in the primary outcome of improvement in fibrosis without worsening of NASH at 72 weeks.
IMM-124E. IMM-124E is a product from colostrum that
concentrates anti-E. coli lipopolysaccharide IgG. IMM124E’s proposed mechanism for NAFLD treatment is to
reduce inflammation by binding bacterial endotoxins, and
it has shown promise in murine models of colitis.55 Due
to the potential role of endotoxins in the pathogenesis
of NAFLD, IMM-124E is the intervention of interest in a
completed but not yet published phase II RCT by Immuron
Ltd. (NCT02316717).
Silymarin. Silymarin is an antioxidant extract of milk
thistle (Silybum marianum) with potential in reducing lipid
peroxidation and hepatic free radical injury. Navarro et al.
investigated a proprietary silymarin preparation (Legalon)
in a small phase II trial (SyNCH study).56 Adults with a
NAS ≥ 4 without cirrhosis were randomized to 420 mg,
700 mg, or placebo orally 3 times daily for 48–54 weeks
(n = 25–27 per arm). Legalon was not superior to placebo
in reaching the primary outcome of reduction in NAS by
≥ 2 points. Adverse events occurred in the majority of study
participants receiving Legalon (420 mg: 65.4%, 700 mg:
55.6% vs. 48% placebo participants). The most common
reported adverse events were classified as gastrointestinal
or cardiac complaints (not further specified) with no serious
adverse events deemed related to the study drug.
Antifibrotic medications
C-C chemokine receptor 2 and 5 inhibitors. C-C
chemokine receptors 2 and 5 and their ligands contribute to
the development of fibrosis in the context of NASH rendering
inhibition of this pathway as an attractive treatment target.
www.cts-journal.com
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CENTAUR is a large phase IIb trial that investigated the
effectiveness of cenicriviroc (CVC), a dual C-C chemokine
receptors 2 and 5 antagonist, for the treatment of NASH
with fibrosis. In this 2-year study, adults with NASH and
fibrosis stages 1–3 were enrolled and randomized to
receive 150 mg of CVC or placebo once daily for 1 year.
Groups A (CVC) and C (placebo) continued with the same
treatment during year 2, but group B (placebo) crossed
over to CVC during year 2. At the end of year 1, twice as
many patients (20% on CVC vs. 10% on placebo, P = 0.02)
achieved reduction of ≥ 1 stage of fibrosis without NASH
worsening.57 At the end of year 2, the response in terms
of fibrosis reduction was similar between groups A and C.
However, twice as many patients who had responded to
CVC during year 1 had a sustained response during year
2 compared with those receiving placebo (60% on CVC
vs. 30% on placebo). No significant adverse events were
noted. In summary, a small number of patients responded
to the antifibrotic effect of CVC. The long-term impact of
CVC on fibrosis, a slow evolving process, remains to be
determined.
Galectin inhibitors. Galectins are a group of cytosolic
proteins that are upregulated in and contribute to
inflammation and fibrosis. Galectin-3 is secreted specifically
by macrophages and contributes to macrophage function
including in apoptosis, adhesion, and angiogenesis.
Chalassani et al. performed a phase IIb double-blinded
RCT of galectin-3 inhibitor belapectin in adults with
cirrhosis and portal hypertension secondary to NASH.58
After biweekly infusions of 2 or 8 mg/kg belapectin vs.
placebo for 52 weeks (n = 54 in each arm), they found no
significant differences in the primary outcome of reduction
in HVPG. In subgroup analyses, patients without varices
receiving 2 mg/kg belapectin experienced a reduction in
HVPG compared with placebo. Adverse events were similar
across all arms, including placebo, and there were no
differences in complications of cirrhosis between groups.

Phase III companion trials STELLAR-3 and STELLAR-4
investigated 6 or 18 mg daily of oral selonsertib vs. placebo
for 48 weeks in adults with NASH and bridging fibrosis and
NASH with compensated cirrhosis, respectively.61 These
studies had > 300 participants in each intervention arm and
showed no difference with treatment in NASH resolution or
progression to cirrhosis. There was a slight increase in adverse effects in the intervention groups.
SUMMARY AND CONCLUSIONS
In summary, NAFLD is an area of intense investigations
for the identification of the optimal medications that, alone
or in combination, can prevent disease progression and/
or reverse advanced liver disease. In spite of promising
data from phase II trials, the only phase III trial that has
generated encouraging results to date is REGENERATE.
Although obeticholic acid has so far been proven superior
to placebo in improving fibrosis, it is only effective in one
quarter of patients. This suggests that additional effective
medications are still urgently needed, and that NAFLD may
have subgroups responding differently to various medication pathways. For that reason, the results of the currently
enrolling phase III trials are eagerly awaited. It is likely that
in the future, patients with NAFLD will require a combination
of medications with each addressing a different aspect in
the pathogenesis of their particular NAFLD phenotype.
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Apoptosis signal-regulating kinase 1 inhibitors.
Apoptosis signal-regulating kinase 1 (ASK1) inhibition is
another target of interest in NASH, as ASK1 activation leads
to hepatocyte apoptosis, hepatic inflammation, and fibrosis.
Selonsertib (GS-4997) is an ASK1 inhibitor. Simtuzumab,
an antibody against lysyl oxidase-like molecule 2 blocks
collagen and elastin cross-linkage contributing to fibrosis.
In a proof of concept study, Loomba et al. investigated
24 weeks of selonsertib 6 or 18 mg daily orally with
and without weekly 125 mg simtuzumab injections vs.
simtuzumab alone in a phase II randomized open-label
trial in adults with histologically diagnosed NASH with
stage 2 or 3 fibrosis without cirrhosis (n = 10–32 per arm).59
They observed trends to reduction in one or more stages
of liver fibrosis and reduction in progression to cirrhosis
at 24 weeks in patients receiving 18 mg selonsertib.
Simtuzumab had no effect on histology. This had also been
shown in another study previously which was terminated
early due to simtuzumab’s lack of efficacy60. Adverse
effects with selonsertib were mild.
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